O'Brien NA, McDermott MSJ, Conklin D, Luo T, et al. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res 2020;22:89.
PMID: 32795346